<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46232">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504372</url>
  </required_header>
  <id_info>
    <org_study_id>3475-091</org_study_id>
    <secondary_id>2015-000575-27</secondary_id>
    <secondary_id>EORTC-1416-LCG</secondary_id>
    <nct_id>NCT02504372</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)</brief_title>
  <acronym>PEARLS</acronym>
  <official_title>A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ETOP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who
      have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant
      chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is
      that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2015</start_date>
  <completion_date type="Anticipated">August 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Up to 100 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Cancer Specific Survival (LCSS)</measure>
    <time_frame>Up to 100 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1380</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological diagnosis of NSCLC confirmed at surgery, any histology

          -  Union for International Cancer Control (UICC) v7 Stage IB with T â‰¥ 4 cm, II-IIIA
             NSCLC after complete surgical resection with resection margins proved microscopically
             free of disease (R0). Carcinoma in situ can be present at the bronchial margin

          -  Available tumor sample obtained at surgical resection for programmed cell death
             ligand-1 (PD-L1) Immunohistochemistry (IHC) expression assessment

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

          -  Adequate organ function performed within 10 days of treatment initiation

          -  Female participants of childbearing potential must have a negative urine or serum
             pregnancy test at screening (within 72 hours of first dose of study medication). If
             the urine test cannot be confirmed as negative, a serum pregnancy test will be
             required. The serum pregnancy test must be negative for the participant to be
             eligible

          -  Female participants of childbearing potential should be willing to use 2 methods of
             birth control or be surgically sterile, or abstain from heterosexual activity for the
             course of the study through 120 days after the last dose of study treatment

          -  Female participants who are breast feeding should discontinue nursing prior to the
             first dose of study medication and until 120 days after the last study treatment

          -  Male participants should agree to use an adequate method of contraception starting
             with the first dose of study treatment through 120 days after the last dose of study
             treatment

          -  Absence of severe comorbidities that in the opinion of the Investigator might hamper
             the participation to the study and/or the treatment administration

          -  No prior or foreseen neo-adjuvant or adjuvant radiotherapy and/or neo-adjuvant
             chemotherapy

        Exclusion Criteria:

          -  Evidence of disease at clinical examination and/or baseline radiological assessment
             as documented by contrast enhanced chest/upper abdomen CT scan, brain CT/MRI and
             clinical examination

          -  More than 4 cycles of adjuvant therapy

          -  Prior treatment with anti-programmed cell death (anti-PD)-1, anti-PD ligand-1/2,
             anti-CD137, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulators

          -  Live vaccine within 30 days prior to the first dose of study treatment

          -  Current participation or treatment with an investigational agent or use of an
             investigational device within 4 weeks of the first dose of study treatment

          -  History of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive). No
             known active Hepatitis B or C

          -  Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in
             the last 3 days prior to the first dose of study treatment

          -  History of interstitial lung disease or (non-infectious) pneumonitis that required
             oral or IV steroids (other than COPD exacerbation) or current pneumonitis

          -  Active autoimmune disease that has required systemic treatment in past 2 years

          -  History of a hematologic or primary solid tumor malignancy, unless in remission for
             at least 5 years with the exception of pT1-2 prostatic cancer Gleason score &lt; 6,
             superficial bladder cancer, non melanomatous skin cancer or carcinoma in situ of the
             cervix

          -  Previous allogeneic tissue/solid organ transplant

          -  Active infection requiring therapy

          -  Surgery- or chemotherapy-related toxicity not resolved to Grade 1 with the exception
             of alopecia, fatigue, neuropathy and lack of appetite /nausea

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of study treatment

          -  Participant will not be eligible if the participant is or has an immediate family
             member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational
             site or Sponsor staff directly involved with this trial, unless prospective site
             Review Board approval is given allowing exception to this criterion for a specific
             participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>MSD Osterreich GmbH</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Boegl</last_name>
      <phone>43 126044130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Belgium BVBA/SPRL</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Denayer</last_name>
      <phone>32 2 776 60 28</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Lassota</last_name>
      <phone>45 44824475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme OU</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>+46 (0) 8Ã½578Ã½135 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Blazy</last_name>
      <phone>33 147548990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vianex, S.A. / MSD</name>
      <address>
        <city>Alimos</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lazaros Poughias</last_name>
      <phone>30 2109897322</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Pharma Hungary Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szabolcs Barotfi</last_name>
      <phone>36 1 888 5300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Ireland (Human Health) Ltd.</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colm Galligan</last_name>
      <phone>353 12998700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Co. Ltd.</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gally Teper</last_name>
      <phone>972-9-9533310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Italia S.r.l.</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Nardini</last_name>
      <phone>39 06 361911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD K.K.</name>
      <address>
        <city>Chiyoda-Ku, Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Japan Call Center</last_name>
      <phone>81-3-6272-1957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme BV</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Doornebos</last_name>
      <phone>31 23 515 3362</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Polska Sp. Z o.o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Johansson</last_name>
      <phone>48 22Ã½478 43 24</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Lda.</name>
      <address>
        <city>Paco Darcos</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Maria Nogueira</last_name>
      <phone>351-21-4465890</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Inovativna zdravilla</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karmen Letonja</last_name>
      <phone>386 15204214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Mateos Chacon</last_name>
      <phone>(0034) 913210600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD International GmbH</name>
      <address>
        <city>Lucerne 6</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Mossdorf</last_name>
      <phone>41 58 618 33 79</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ltd.</name>
      <address>
        <city>Hoddesdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Toms</last_name>
      <phone>+44 (0) 1992 452475</phone>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>July 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>PDL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
